SAGE Therapeutics Inc - ESG Rating & Company Profile powered by AI
The dashboard includes a questions and answers table about SAGE Therapeutics Inc. This analysis of SAGE Therapeutics Inc uses data from across the web and also from public filings by SAGE Therapeutics Inc. The Sustainability rating for SAGE Therapeutics Inc represents its reporting of the United Nations Sustainable Development Goals.
SAGE Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.3; made up of an environmental score of 2.7, social score of 4.6 and governance score of 2.7.
3.3
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1234 | Quanterix Corp | 3.4 | Medium |
| 1234 | X4 Pharmaceuticals Inc | 3.4 | Medium |
| 1253 | SAGE Therapeutics Inc | 3.3 | Medium |
| 1253 | Calithera Biosciences Inc | 3.3 | Medium |
| 1253 | Cara Therapeutics Inc | 3.3 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does SAGE Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes SAGE Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes SAGE Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes SAGE Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes SAGE Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes SAGE Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes SAGE Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes SAGE Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid SAGE Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes SAGE Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas SAGE Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes SAGE Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes SAGE Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs SAGE Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes SAGE Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes SAGE Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes SAGE Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for SAGE Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.